174 related articles for article (PubMed ID: 31605337)
41. ASO Author Reflections: Molecular Profiling Can Provide Personalized Clinical Guidance in the Management of Peritoneal Malignancies.
Moaven O; Miller LD; Levine EA
Ann Surg Oncol; 2020 Dec; 27(13):5024-5025. PubMed ID: 32749622
[No Abstract] [Full Text] [Related]
42. ASO Author Reflections: Improving Outcomes in Diffuse Malignant Peritoneal Mesothelioma: Challenges and Opportunities.
Leinwand JC; Kluger MD
Ann Surg Oncol; 2020 Dec; 27(Suppl 3):742-743. PubMed ID: 32239340
[No Abstract] [Full Text] [Related]
43. Neoadjuvant Chemotherapy Increases R0 Cytoreduction Rate But Does Not Improve Final Outcome in Advanced Epithelial Ovarian Cancer.
Medina-Franco H; Cortés-González R; Lambreton-Hinojosa F; Fimbres-Morales A; Vargas-Siordia JC
Ann Surg Oncol; 2017 May; 24(5):1330-1335. PubMed ID: 27995454
[TBL] [Abstract][Full Text] [Related]
44. Prognostic Factors in Patients Undergoing Primary Cytoreductive Surgery for FIGO Stage IIIC Ovarian, Tubal or Peritoneal Cancer.
Kaban A; Topuz S; Saip P; Sözen H; Salihoğlu Y
J Obstet Gynaecol Can; 2018 Apr; 40(4):447-453. PubMed ID: 29055648
[TBL] [Abstract][Full Text] [Related]
45. ASO Author Reflections: Repeated Intraperitoneal Paclitaxel with Systemic Chemotherapy as the First-Line Treatment for Peritoneal Malignancy.
Kitayama J; Saito S; Yamaguchi H; Lefor AK; Ishigami H; Sata N
Ann Surg Oncol; 2021 Jul; 28(7):3871-3872. PubMed ID: 33432487
[No Abstract] [Full Text] [Related]
46. ASO Author Reflections: Normothermic Intraperitoneal Chemotherapy Long-Term for Malignant Peritoneal Mesothelioma.
Sugarbaker PH
Ann Surg Oncol; 2021 Nov; 28(12):7118-7119. PubMed ID: 33909181
[No Abstract] [Full Text] [Related]
47. ASO Author Reflections: Predicting Hyperthermia and Its Effect in Patients with Peritoneal Surface Malignancies.
Guerra-Londono CE; Owusu-Agyemang P; Corrales G; Rofaeil MM; Feng L; Fournier K; Cata JP
Ann Surg Oncol; 2022 Mar; 29(3):2100-2101. PubMed ID: 34713370
[No Abstract] [Full Text] [Related]
48. Minimally invasive secondary cytoreduction plus HIPEC versus open surgery plus HIPEC in isolated relapse from ovarian cancer: a retrospective cohort study on perioperative outcomes.
Fagotti A; Costantini B; Gallotta V; Cianci S; Ronsini C; Petrillo M; Pacciani M; Scambia G; Fanfani F
J Minim Invasive Gynecol; 2015; 22(3):428-32. PubMed ID: 25461683
[TBL] [Abstract][Full Text] [Related]
49. Validation of a peritoneal surface disease severity score in stage IIIC-IV ovarian cancer treated with cytoreduction and hyperthermic intraperitoneal chemotherapy.
Pedro Antonio CC; Álvaro Jesús GR; José G; Elena G; Alida G; Francisco ML; Guillermo CDC; Pascual P
Surg Oncol; 2019 Mar; 28():57-61. PubMed ID: 30851912
[TBL] [Abstract][Full Text] [Related]
50. ASO Author Reflections: Pleural Spread of Peritoneal Malignancies: When Heated Chemoperfusion Can Save the Day.
Nikiforchin A; King MC; Gushchin V; Sardi A
Ann Surg Oncol; 2021 Dec; 28(13):9136-9137. PubMed ID: 34313886
[No Abstract] [Full Text] [Related]
51. Intraperitoneal chemotherapy for ovarian cancer.
Walker JL
Gynecol Oncol; 2016 Jul; 142(1):1-2. PubMed ID: 27328898
[No Abstract] [Full Text] [Related]
52. Impact of Laparoscopy to Assess Resectability in Stage IIIC Epithelial Ovarian, Tubal and Peritoneal Cancer Patients.
Sánchez-Iglesias JL; Perez-Benavente A; Correa-Paris A; De la Torre Fernandez de Vega J; Carbonell Socias M; Gil-Moreno A
Gynecol Obstet Invest; 2019; 84(3):259-267. PubMed ID: 30428466
[TBL] [Abstract][Full Text] [Related]
53. MRI with diffusion-weighted imaging to predict feasibility of complete cytoreduction with the peritoneal cancer index (PCI) in advanced stage ovarian cancer patients.
Engbersen MP; Van' T Sant I; Lok C; Lambregts DMJ; Sonke GS; Beets-Tan RGH; van Driel WJ; Lahaye MJ
Eur J Radiol; 2019 May; 114():146-151. PubMed ID: 31005166
[TBL] [Abstract][Full Text] [Related]
54. A novel classification of residual disease after interval debulking surgery for advanced-stage ovarian cancer to better distinguish oncologic outcome.
Manning-Geist BL; Hicks-Courant K; Gockley AA; Clark RM; Del Carmen MG; Growdon WB; Horowitz NS; Berkowitz RS; Muto MG; Worley MJ
Am J Obstet Gynecol; 2019 Oct; 221(4):326.e1-326.e7. PubMed ID: 31082382
[TBL] [Abstract][Full Text] [Related]
55. ASO Author Reflections: A Novel Tool to Assess and Describe HIPEC Complications.
Dumitra S; Lee B
Ann Surg Oncol; 2019 Dec; 26(Suppl 3):557-558. PubMed ID: 30600405
[No Abstract] [Full Text] [Related]
56. A novel technique: Carbon dioxide gas-assisted total peritonectomy, diaphragm and intestinal meso stripping in open surgery for advanced ovarian cancer (Çukurova technique).
Khatib G; Guzel AB; Gulec UK; Vardar MA
Gynecol Oncol; 2017 Sep; 146(3):674-675. PubMed ID: 28720378
[TBL] [Abstract][Full Text] [Related]
57. ASO Author Reflections: Systematic Lymph Node Dissection in Ovarian Cancer Under Attack.
Heitz F; Harter P; du Bois A
Ann Surg Oncol; 2018 Dec; 25(Suppl 3):884-885. PubMed ID: 30421056
[No Abstract] [Full Text] [Related]
58. Evaluation of a Simple and Safe Tumor Drilling Technique to Potentiate the Effect of Intraperitoneal Chemotherapy in the Treatment of Recurrent Epithelial Ovarian, Tubal, and Peritoneal Cancer: A Matched Retrospective Cohort Study.
Chao WT; Chien CH; Lai CR; Wu HJ; Chuang CM
Cancer Control; 2019; 26(1):1073274819863778. PubMed ID: 31343898
[TBL] [Abstract][Full Text] [Related]
59. Step by step right upper quadrant cytoreduction guided by computed tomography in advanced ovarian cancer.
Celik M; Tasci T; Basaran D; Tulunay G
Gynecol Oncol; 2015 Dec; 139(3):582-3. PubMed ID: 26456140
[No Abstract] [Full Text] [Related]
60. Pre-operative prediction of residual disease after interval cytoreduction for epithelial ovarian cancer using HE4.
Lof P; van de Vrie R; Korse CM; van Driel WJ; van Gent MDJM; Karlsen MA; Amant F; Lok CAR
Int J Gynecol Cancer; 2019 Oct; 29(8):1304-1310. PubMed ID: 31515411
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
